Disease-Modifying Therapies

Disease-modifying therapies (DMT's) can affect the course of MS. Although not a cure, disease-modifying therapies act to reduce the number and severity of MS relapses. They also reduce the number of new MS lesions. It is not yet known whether these drugs will slow down the rate of disability in the long-term.

Information on all the DMTs that are currently available in Ireland can be found in this table, including administration methods, possible side effects and how the medication is paid for. More detailed information on each medication is available in the information sheets below.


Aubagio is prescribed to adults with relapsing remitting MS.


Avonex is the brand name for a disease modifying treatment for people with MS. The active ingredient is interferon beta 1a, which comes in a solution or powder, and is given by injection.


Betaferon (interferon beta-1b) is a type of medicine known as an interferon, which is used to treat MS. Interferons are proteins found naturally in the body, which may help boost the immune system and fight infections.

Brabio (glatiramer acetate)

Brabio is the brand name for Glatiramer Acetate injection. Brabio is a synthetic combination of four amino acids, resembling the myelin protein which surrounds nerve fibres. It is thought to reduce the immune response that attacks myelin. Brabio is a disease modifying therapy available to people living with relapsing-remitting MS.


Copaxone is the brand name for glatiramer acetate injection. Copaxone is a mixture of four amino acids, the natural building blocks of proteins in the body. Copaxone is the first non-steroidal, non-interferon MS drug therapy available to people living with relapsing-remitting MS.


Fampyra is a slow-release oral tablet for the symptomatic treatment of walking impairment in adults with multiple sclerosis.


Gilenya (Fingolimod) is a new type of therapy that can be taken orally rather than by injection or infusion. It is known as a disease modifying therapy (DMT) and targets the immune system to reduce relapses. 


Lemtrada (alemtuzumab) is an experimental drug treatment (an annual infusion) that is currently being tested in clinical trials for people with relapsing remitting MS. The new marketing name for Alemtuzumab is Lemtrada.


Plegridy can be prescribed for adults with relapsing remitting MS.


Rebif belongs to a class of medicines known as interferons. These are natural substances that transmit messages between cells. Rebif is a highly purified soluble protein, which is similar to the natural interferon beta that is produced in the human body. It has been shown to reduce the number and the severity of relapses and to slow the progression of disability in patients with MS

Tecfidera (dimethyl fumarate)

Tecifidera (dimethyl fumarate or DMF) is a drug for treating relapsing-remitting multiple sclerosis (RRMS). 


Tysabri is given to patients with highly active forms of relapsing-remitting MS or those who have failed on other disease-modifying therapies. ‘Highly active’ is defined as two or more disabling relapses in a year and the presence of more lesions on the brain in an MRI scan.

Zinbryta (Daclizumab)

On 7th March 2018, the European Medicines Agency withdraw their license for Zinbryta due to reports of serious adverse events. >> Read more 

Latest News

More news

What's hot


Enter our 2020 Calendar Competition!

Calling all budding photographers! Enter our competition to see YOUR photo in our new calendar!

Find out more

Events Calendar

» Our next Event

21 June 2019: Open coffee morning and information on MS and the Clare Branch, everybody welcome.

View all events


If you'd like to receive e-news updates from The Society please enter your email address below. If you want to know more about how we manage personal data then please see our privacy policy.

My local MSI

Map of MS Ireland's service areas South Mid West West Midlands South East North East North West North Dublin City and Fingal South West Dublin and Kildare South East Dublin and Wicklow